背景:评估经皮穿刺活检和微波消融术(B+MWA)在接受利伐沙班作为桥接治疗的肺结节(PNs)患者中的安全性和有效性。
方法:该研究包括从2020年1月1日至2021年12月31日接受187次B+MWA治疗的187例PNs患者。将入选患者分为两组:A组,在手术前五天接受抗血栓治疗,并在住院期间接受利伐沙班作为桥接药物,B组,没有抗血栓治疗的人。有关技术成功率的信息,活检阳性率,完全烧蚀率,收集并分析主要并发症。
结果:A组包括53名患者,B组包括134名患者。两组的技术成功率均为100%。活检阳性率分别为88.68%和91.04%,分别(p=0.6211,X2=0.2443)。在A组和B组中,6、12和24个月的完全消融率分别为100.0%和99.25%,96.23%与96.27%,分别为88.68%和89.55%,分别。两组在出血和血栓性并发症方面差异无统计学意义。无5级并发症发生。
结论:通常认为接受利伐沙班抗血栓治疗的患者接受B+MWA治疗PNs是安全有效的。
BACKGROUND: To evaluate the safety and efficacy of percutaneous biopsy and microwave ablation (B + MWA) in patients with pulmonary nodules (PNs) who are receiving antithrombotic therapy by rivaroxaban as bridging therapy.
METHODS: The study comprised 187 patients with PNs who underwent 187 B + MWA sessions from January 1, 2020, to December 31, 2021. The enrolled patients were divided into two groups: Group A, who received antithrombotic therapy five days before the procedure and received rivaroxaban as a bridging drug during hospitalization, and group B, who had no antithrombotic treatment. Information about the technical success rate, positive biopsy rate, complete ablative rate, and major complications were collected and analyzed.
RESULTS: Group A comprised 53 patients and group B comprised 134 patients. The technical success rate was 100% in both groups. The positive biopsy rates were 88.68% and 91.04%, respectively (p = 0.6211, X2 = 0.2443). In groups A and B, the complete ablative rates at 6, 12, and 24 months were 100.0% versus 99.25%, 96.23% versus 96.27%, and 88.68% versus 89.55%, respectively. There were no significant differences in bleeding and thrombotic complications between the two groups. No grade 5 complications occurred.
CONCLUSIONS: It is generally considered safe and effective that patients who are on antithrombotic therapy by rivaroxaban as bridging to undergo B + MWA for treating PNs.